RJ
Raghavendra Jayakumar Yencharla
About Raghavendra Jayakumar Yencharla
Data last updated:
Raghavendra Jayakumar Yencharla has 12 years in corporate governance. Holds Designated Partner role. Currently with 1 company, including Posilive Pharmaceuticals Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Posilive Pharmaceuticals Llp at ₹11.66 Cr (FY 2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Posilive Pharmaceuticals Llp AAC-8330 | Designated Partner | 21 Oct 2014 | 2014 | ₹11.66 Cr (FY 2022) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Raghavendra Jayakumar Yencharla
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Raghavendra Jayakumar Yencharla
Raghavendra Jayakumar Yencharla has 12 years in corporate governance. Holds Designated Partner role. Currently with 1 company, including Posilive Pharmaceuticals Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Posilive Pharmaceuticals Llp at ₹11.66 Cr (FY 2022).
Raghavendra Jayakumar Yencharla is associated with 1 company as Designated Partner, including Posilive Pharmaceuticals Llp (₹11.66 Cr).
Raghavendra Jayakumar Yencharla has expertise in General Business.
Raghavendra Jayakumar Yencharla has 12 years in corporate governance.
By reported revenue, the largest current company of Raghavendra Jayakumar Yencharla is Posilive Pharmaceuticals Llp, with revenue of ₹11.66 Cr (FY 2022).
Raghavendra Jayakumar Yencharla currently holds positions at 1 company: Posilive Pharmaceuticals Llp (₹11.66 Cr).